Calithera Biosciences, Inc. (CALA) |
|
4.46 -0.01 (-0.22%)
|
08-18 06:55 |
|
Open: |
4.25 |
Pre. Close: |
4.47 |
|
High:
|
4.52 |
Low:
|
4.1607 |
|
Volume:
|
68,187 |
Market Cap:
|
22(M) |
|
|
|
|
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.52 - 4.55 |
4.55 - 4.56 |
|
Low:
|
4.11 - 4.14 |
4.14 - 4.16 |
|
Close:
|
4.42 - 4.46 |
4.46 - 4.49 |
|
Technical analysis |
as of: 2022-08-17 4:22:03 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 5.27  One year: 6.16 |
| Support: |
Support1: 3.25 Support2: 2.47 |
| Resistance: |
Resistance1: 4.51 Resistance2: 5.27 |
| Pivot: |
3.74 |
| Moving Average: |
MA(5): 4.2 MA(20): 3.6
MA(100): 4.16  MA(250): 15.11 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 97.6 %D(3): 94.5 |
| RSI: |
RSI(14): 68.1 |
| 52-week: |
High: 49.79 Low: 0.18 |
| Average Vol(K): |
3-Month: 170 (K) 10-Days: 131 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CALA ] has closed below upper band by 12.9%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 18 Aug 2022
Hotel Cala di Volpe review: holiday like a royal at Sardinia's A-List hotspot - HELLO!
Wed, 17 Aug 2022
Panic in Mallorca after tourist train flips over, passengers thrown from vehicle - Majorca Daily Bulletin
Wed, 17 Aug 2022
30 Best Beaches in Costa Brava To Visit (2022) - The Trend Spotter
Mon, 15 Aug 2022
Calithera Biosciences (CALA) Q2 2022 Earnings Call Transcript - The Motley Fool
Mon, 15 Aug 2022
Calithera Biosciences reports Q2 results (NASDAQ:CALA) - Seeking Alpha
Tue, 09 Aug 2022
Cala contributes nearly £100m to L&G half-year profits - Construction Index
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
5 (M) |
|
% Held by Insiders
|
4.38e+006 (%) |
|
% Held by Institutions
|
1.1 (%) |
|
Shares Short
|
116 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.0702e+008 |
|
EPS Est Next Qtl
|
-0.24 |
|
EPS Est This Year
|
-0.82 |
|
EPS Est Next Year
|
-1.05 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
100.4 |
|
Return on Equity (ttm)
|
-83.4 |
|
Qtrly Rev. Growth
|
9.75e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-88.6 |
|
EBITDA (p.s.)
|
5.24194e+006 |
|
Qtrly Earnings Growth
|
-28.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-60 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.06 |
|
Price to Cash Flow
|
-10.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
144170 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
